ServiceUpdated on 22 June 2025
SynergyFinder
About
To identify the right combination of drug candidates with standards of care or new drugs, Oncolines offers three different synergy platforms. The SynergyScreen™ is a high-throughput screen in which your novel drug will be screened against a library of 42 selected reference anti-cancer agents. This unbiased approach helps with exploring possible synergistic drug groups of a drug candidate compound. Once an idea about the synergistic partners of the drug has been identified, synergistic effects can be confirmed in either the SynergyFinder™ or the combination matrix. In SynergyFinder™, equipotent mixtures of two (or more) drugs are tested in three fixed ratios (1:1, 4:1 and 1:4) based on IC50 values. Synergy is evaluated by curve shift analysis and calculation of the Combination Index (CI). In the combination matrix, two compounds are combined in six points dilution range. Synergy is evaluated by calculating the Bliss score.
Type
- Development
- Consulting
Applies to
- Innovative therapies - Immune cell therapy
- Innovative therapies - Nanomedicine
- Innovative therapies - Precision medicine
- Innovative human-based test models - 2D & 3D in vitro cell culture models
- Innovative human-based test models - 3D spheroids
- Development stages and support fuctions - Pre-clinical research and development
- Development stages and support fuctions - Clinical research and development
Organisation
Similar opportunities
Service
Oncolines cancer cell panel profiling
- Consulting
- Development
- Innovative therapies - Precision medicine
- Innovative therapies - Immune cell therapy
- Innovative human-based test models - 3D spheroids
- Innovative human-based test models - 2D & 3D in vitro cell culture models
- Development stages and support fuctions - Clinical research and development
- Development stages and support fuctions - Pre-clinical research and development
Guido Zaman
Managing Director at Oncolines B.V.
Oss, Netherlands
Service
- Consulting
- Development
- Innovative therapies - Precision medicine
- Innovative therapies - Immune cell therapy
- Innovative human-based test models - 3D spheroids
- Innovative human-based test models - 2D & 3D in vitro cell culture models
- Development stages and support fuctions - Early discovery / basic research
- Development stages and support fuctions - Technology development and validation
- Development stages and support fuctions - Pre-clinical research and development
Guido Zaman
Managing Director at Oncolines B.V.
Oss, Netherlands
Service
- Innovative therapies - RNA therapy
- Innovative therapies - Gene therapy
- Innovative therapies - Nanomedicine
- Innovative therapies - Precision medicine
- Innovative therapies - Immune cell therapy
- Innovative human-based test models - 3D spheroids
- Innovative human-based test models - 3D spheroids
- Innovative human-based test models - Organ-on-Chip
- Innovative human-based test models - In silico human models
- Innovative human-based test models - Bioprinted tissues and constructs
- Innovative human-based test models - Assembloids and multi-tissue models
- Development stages and support fuctions - Contract research (CRO / CRMO)
- Innovative human-based test models - 2D & 3D in vitro cell culture models
- Development stages and support fuctions - Early discovery / basic research
- Development stages and support fuctions - Technology development and validation
- Development stages and support fuctions - Pre-clinical research and development
Monique van Scherpenzeel
CEO and founder at GlycoMScan B.V.
Arnhem, Netherlands